A share price of Protagonist Therapeutics Inc [PTGX] is currently trading at $46.28, up 1.05%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTGX shares have gain 13.18% over the last week, with a monthly amount drifted -14.85%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on December 06, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $47. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $62. On November 05, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $58 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on September 24, 2024. Truist initiated its recommendation with a Buy and recommended $60 as its price target on September 09, 2024. CapitalOne started tracking with a Overweight rating for this stock on October 30, 2023, and assigned it a price target of $32.
Protagonist Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $24.22 and $60.60. Currently, Wall Street analysts expect the stock to reach $70.25 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $46.28 at the most recent close of the market. An investor can expect a potential return of 51.79% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Trailing Twelve Months sales for Protagonist Therapeutics Inc [NASDAQ:PTGX] were 434.43M which represents 184.40% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.58%, Pretax Profit Margin comes in at 0.64%, and Net Profit Margin reading is 0.63%. To continue investigating profitability, this company’s Return on Assets is posted at 0.37, Equity is 0.48 and Total Capital is 0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.76 points at the first support level, and at 45.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.83, and for the 2nd resistance point, it is at 47.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Protagonist Therapeutics Inc [NASDAQ:PTGX] is 12.48. Further, the Quick Ratio stands at 12.48, while the Cash Ratio is 2.05. Considering the valuation of this stock, the price to sales ratio is 6.54, the price to book ratio is 4.18 and price to earnings (TTM) ratio is 11.00.
Transactions by insiders
Recent insider trading involved Waddill William D., Director, that happened on Mar 17 ’25 when 4000.0 shares were sold. Director, WILLIAM D WADDILL completed a deal on Mar 17 ’25 to buy 4000.0 shares. Meanwhile, Chief Medical Officer MOLINA ARTURO MD sold 30514.0 shares on Mar 13 ’25.
